Open Access. Powered by Scholars. Published by Universities.®
Pharmacy and Pharmaceutical Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Pharmacy and Pharmaceutical Sciences
B-Cell Monoclonal Antibodies For Management Of Relapse Remitting Multiple Sclerosis: A Cost Effectiveness Analysis, Sarah Glover
B-Cell Monoclonal Antibodies For Management Of Relapse Remitting Multiple Sclerosis: A Cost Effectiveness Analysis, Sarah Glover
Pharmaceutical Sciences ETDs
Multiple sclerosis (MS) is a neurodegenerative disease in which the central nervous system’s myelin sheath is degraded by auto-immune cells. Relapse remitting multiple sclerosis (RRMS) is the most common MS phenotype, accounting for ~85% of new diagnoses. Disease modifying therapies (DMTs) are used in RRMS to reduce the frequency of relapses and prevent disability progression. The present study performed a cost effectiveness analysis of three B-cell depleting monoclonal antibody DMTs: ocrelizumab, ofatumumab and rituximab, in comparison to commonly utilized interferon beta-1a (IFN-B1a). A Markov model was created to determine the impact of selected DMTs on the number of …